Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 20/20 | 0.51 |
| ▸ | CASP6 | P55212 | 13/20 | 0.48 |
| ▸ | CASP8 | Q14790 | 13/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1897560 | 0.92 | CASP3 (0.60) | CASP3CASP6CASP8 | |
| SCHEMBL3285382 | 0.91 | CASP3 (0.50) | CASP3CASP6CASP8 | |
| SCHEMBL4565945 | 0.87 | CASP3 (0.38) | CASP3CASP6CASP8 | |
| SCHEMBL1893933 | 0.86 | CASP3 (0.57) | CASP3CASP6CASP8 | |
| SCHEMBL4556858 | 0.86 | CASP3 (0.62) | CASP3CASP6CASP8 | |
| SCHEMBL4556832 | 0.83 | CASP3 (0.56) | CASP3CASP6CASP8 | |
| SCHEMBL15949720 | 0.82 | CASP3 (0.42) | CASP3CASP6CASP8 | |
| SCHEMBL4556879 | 0.82 | CASP3 (0.59) | CASP3CASP6CASP8 | |
| SCHEMBL4556825 | 0.81 | CASP3 (0.57) | CASP3CASP6CASP8 | |
| SCHEMBL1898227 | 0.81 | CASP3 (0.58) | CASP3CASP6CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3142649-B1 | TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE WITH CASPASE INHIBITOR EMRICASAN | CONATUS PHARMACEUTICALS INC (US) | 2019-07-24 | — | — | EP | disclosed |
| EP-3444011-A1 | TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE WITH EMRICASAN | Conatus Pharmaceuticals, Inc. (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-3397251-A1 | METHODS OF USING CASPASE INHIBITORS IN TREATMENT OF LIVER DISEASE | Conatus Pharmaceuticals, Inc. (US) | 2018-11-07 | — | — | EP | disclosed |
| WO-2017117478-A1 | METHODS OF USING CASPASE INHIBITORS IN TREATMENT OF LIVER DISEASE | CONATUS PHARMACEUTICALS INC. (US) | 2017-07-06 | — | — | WO | disclosed |
| US-20170100448-A1 | TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE WITH CASPASE INHIBITORS | CONATUS PHARMACEUTICALS INC (US) | 2017-04-13 | — | — | US | disclosed |
| US-20160213736-A1 | TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE | CONATUS PHARMACEUTICALS, INC. | 2016-07-28 | — | — | US | disclosed |
| EP-1754475-B1 | Use of C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS INC (US) | 2009-09-16 | — | — | EP | disclosed |
| US-7183260-B2 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| EP-1754475-A1 | Use of C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases | Idun Pharmaceuticals, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1091930-B1 | C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS INC (US) | 2006-12-13 | — | — | EP | disclosed |
| US-7053056-B2 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20050020504-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | US | disclosed |
| US-6197750-B1 | ENZYME INHIBITORS; ANTIINFLAMMATORY AGENTS | IDUN PHARMACEUTICALS, INC. | 2001-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170100448-A1 | TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE WITH CASPASE INHIBITORS | CASP1, CASP2, CASP5 | CASP3 6/4885CASP6 10/4885CASP8 8/4885 |
| US-20160213736-A1 | TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE | CASP1, SERPINB1, CASP2 | CASP3 8/4885CASP6 12/4885CASP8 15/4885 |
| US-20050020504-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | CASP3, DPP3, IAPP | CASP3 1/4885CASP6 22/4885CASP8 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.